Inhibition of Mast Cell Function and Proliferation by mTOR Activator MHY1485
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Mast cells integrate innate and adaptive immunity and are implicated in pathophysiological conditions, including allergy, asthma, and anaphylaxis. Cross-linking of the high-affinity IgE receptor (FcεRI) initiates diverse signal transduction pathways and induces release of proinflammatory mediators by mast cells. In this study, we demonstrated that hyperactivation of mechanistic target of rapamycin (mTOR) signaling using the mTOR activator MHY1485 suppresses FcεRI-mediated mast cell degranulation and cytokine secretion. MHY1485 treatment increased ribosomal protein S6 kinase (S6K) and eukaryotic translation initiation factor 4E-binding protein 1 (4E-BP1) phosphorylation, which are downstream targets of mTOR complex 1 (mTORC1), but decreased phosphorylation of Akt on mTOR complex 2 (mTORC2) target site serine 473. In addition, this activator decreased β-hexosaminidase, IL-6, and tumor necrosis factor α (TNF-α) release in murine bone marrow-derived mast cells (BMMCs) after FcεRI stimulation. Furthermore, MHY1485-treated BMMCs showed significantly decreased proliferation when cultured with IL-3. These findings suggested hyperactivation of mTORC1 as a therapeutic strategy for mast cell-related diseases.
Abstract
Mast cells integrate innate and adaptive immunity and are implicated in pathophysiological conditions, including allergy, asthma, and anaphylaxis. Cross-linking of the high-affinity IgE receptor (FcεRI) initiates diverse signal transduction pathways and induces release of proinflammatory mediators by mast cells. In this study, we demonstrated that hyperactivation of mechanistic target of rapamycin (mTOR) signaling using the mTOR activator MHY1485 suppresses FcεRI-mediated mast cell degranulation and cytokine secretion. MHY1485 treatment increased ribosomal protein S6 kinase (S6K) and eukaryotic translation initiation factor 4E-binding protein 1 (4E-BP1) phosphorylation, which are downstream targets of mTOR complex 1 (mTORC1), but decreased phosphorylation of Akt on mTOR complex 2 (mTORC2) target site serine 473. In addition, this activator decreased β-hexosaminidase, IL-6, and tumor necrosis factor α (TNF-α) release in murine bone marrow-derived mast cells (BMMCs) after FcεRI stimulation. Furthermore, MHY1485-treated BMMCs showed significantly decreased proliferation when cultured with IL-3. These findings suggested hyperactivation of mTORC1 as a therapeutic strategy for mast cell-related diseases.
참고문헌 (28)
- Okayama Y, "Development, migration, and survival of mast cells", Immunol Res, 34, pp.97~115 (2006)[DOI]
- Metcalfe DD, "Mast cells", Physiol Rev, 77, pp.1033~1079 (1997)[DOI]
- Galli SJ, "IgE and mast cells in allergic disease", Nat Med, 18, pp.693~704 (2012)[DOI]
- Theoharides TC, "Mast cells and inflammation", Biochim Biophys Acta, 1822, pp.21~33 (2012)[DOI]
- Sibilano R, "Mast cell activation: a complex interplay of positive and negative signaling pathways", Eur J Immunol, 44, pp.2558~2566 (2014)[DOI]
- Biethahn K, "miRNA-155 controls mast cell activation by regulating the <TEX>$PI3K{\gamma}$<", TEX> pathway and anaphylaxis in a mouse model, 2014, pp.69, 752~762
- Laffargue M, "Phosphoinositide 3-kinase <TEX>${\gamma}$<", TEX> is an essential amplifier of mast cell function, 2002, pp.16, 441~451
- Weichhart T, "Regulation of innate immune cell function by mTOR", Nat Rev Immunol, 15, pp.599~614 (2015)[DOI]
- Jones RG, "Mentoring immunity: mTOR signaling in the development and function of tissue-resident immune cells", Immunity, 46, pp.730~742 (2017)[DOI]
- Kim MS, "Activation and function of the mTORC1 pathway in mast cells", J Immunol, 180, pp.4586~4595 (2008)[DOI]
- Shin J, "Regulation of mast cell survival and function by tuberous sclerosis complex 1", Blood, 119, pp.3306~3314 (2012)[DOI]
- Choi YJ, "Inhibitory effect of mTOR activator MHY1485 on autophagy: suppression of lysosomal fusion", PLoS One, 7, pp.e43418~ (2012)[DOI]
- Shin J, "Negative control of mast cell degranulation and the anaphylactic response by the phosphatase lipin1", Eur J Immunol, 43, pp.240~248 (2013)[DOI]
- Fukuishi N, "Does <TEX>${\beta}$<", TEX>-hexosaminidase function only as a degranulation indicator in mast cells? The primary role of <TEX>${\beta}$<, J Immunol, pp.2014, 193[DOI]
- Laplante M, "mTOR signaling in growth control and disease", Cell, 149, pp.274~293 (2012)[DOI]
- Yang B, "MHY1485 ameliorates UV-induced skin cell damages via activating mTOR-Nrf2 signaling", Oncotarget, 8, pp.12775~12783 (2017)
- Zhao S, "MHY1485 activates mTOR and protects osteoblasts from dexamethasone", Biochem Biophys Res Commun, 481, pp.212~218 (2016)[DOI]
- Alfrson J, "Proapoptotic Bcl-2 family member Bim is involved in the control of mast cell survival and is induced together with Bcl-XL upon IgE-receptor activation", Cell Death Differ, 12, pp.136~144 (2005)[DOI]
- Mekori YA, "IL-3-dependent murine mast cells undergo apoptosis on removal of IL-3. Prevention of apoptosis by c-kit ligand", J Immunol, 151, pp.3775~3784 (1993)
- Smrz D, "mTORC1 and mTORC2 differentially regulate homeostasis of neoplastic and non-neoplastic human mast cells", Blood, 118, pp.6803~6813 (2011)[DOI]
- Julien LA, "mTORC1-activated S6K1 phosphorylates Rictor on threonine 1135 and regulates mTORC2 signaling", Mol Cell Biol, 30, pp.908~921 (2010)[DOI]
- Dibble CC, "Characterization of Rictor phosphorylation sites reveals direct regulation of mTOR complex 2 by S6K1", Mol Cell Biol, 29, pp.5657~5670 (2009)[DOI]
- Treins C, "Rictor is a novel target of p70 S6 kinase-1", Oncogene, 29, pp.1003~1016 (2010)[DOI]
- Takayama G, "Class I PI3K-mediated Akt and ERK signals play a critical role in <TEX>$Fc{\varepsilon}RI$<", TEX>-induced degranulation in mast cells, 2013, pp.25, 215~220
- Kitaura J, "Akt-dependent cytokine production in mast cells", J Exp Med, 192, pp.729~740 (2000)[DOI]
- Inoki K, "Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling", Genes Dev, 17, pp.1829~1834 (2003)[DOI]
- Yasuda S, "Activation of Rheb, but not of mTORC1, impairs spine synapse morphogenesis in tuberous sclerosis complex", Sci Rep, 4, pp.5155~ (2014)
- Woodford MR, "Tumor suppressor Tsc1 is a new Hsp90 co-chaperone that facilitates folding of kinase and non-kinase clients", EMBO J, 36, pp.3650~3665 (2017)[DOI]